145 related articles for article (PubMed ID: 38157867)
1. An orally available Ca
Kutzsche J; Guzman GA; Willuweit A; Kletke O; Wollert E; Gering I; Jürgens D; Breitkreutz J; Stark H; Beck-Sickinger AG; Klöcker N; Hidalgo P; Willbold D
Br J Pharmacol; 2024 Jun; 181(12):1734-1756. PubMed ID: 38157867
[TBL] [Abstract][Full Text] [Related]
2. Subcutaneous ω-Conotoxins Alleviate Mechanical Pain in Rodent Models of Acute Peripheral Neuropathy.
Hasan MM; Starobova H; Mueller A; Vetter I; Lewis RJ
Mar Drugs; 2021 Feb; 19(2):. PubMed ID: 33670311
[TBL] [Abstract][Full Text] [Related]
3. Spinal actions of ω-conotoxins, CVID, MVIIA and related peptides in a rat neuropathic pain model.
Jayamanne A; Jeong HJ; Schroeder CI; Lewis RJ; Christie MJ; Vaughan CW
Br J Pharmacol; 2013 Sep; 170(2):245-54. PubMed ID: 23713957
[TBL] [Abstract][Full Text] [Related]
4. A novel series of pyrazolylpiperidine N-type calcium channel blockers.
Subasinghe NL; Wall MJ; Winters MP; Qin N; Lubin ML; Finley MF; Brandt MR; Neeper MP; Schneider CR; Colburn RW; Flores CM; Sui Z
Bioorg Med Chem Lett; 2012 Jun; 22(12):4080-3. PubMed ID: 22608964
[TBL] [Abstract][Full Text] [Related]
5. Challenging the catechism of therapeutics for chronic neuropathic pain: Targeting CaV2.2 interactions with CRMP2 peptides.
Feldman P; Khanna R
Neurosci Lett; 2013 Dec; 557 Pt A(0 0):27-36. PubMed ID: 23831344
[TBL] [Abstract][Full Text] [Related]
6. Analgesic effect of highly reversible ω-conotoxin FVIA on N type Ca2+ channels.
Lee S; Kim Y; Back SK; Choi HW; Lee JY; Jung HH; Ryu JH; Suh HW; Na HS; Kim HJ; Rhim H; Kim JI
Mol Pain; 2010 Dec; 6():97. PubMed ID: 21172037
[TBL] [Abstract][Full Text] [Related]
7. Effects of arginine 10 to lysine substitution on ω-conotoxin CVIE and CVIF block of Cav2.2 channels.
Berecki G; Daly NL; Huang YH; Vink S; Craik DJ; Alewood PF; Adams DJ
Br J Pharmacol; 2014 Jul; 171(13):3313-27. PubMed ID: 24628243
[TBL] [Abstract][Full Text] [Related]
8. Novel analgesic ω-conotoxins from the vermivorous cone snail Conus moncuri provide new insights into the evolution of conopeptides.
Sousa SR; McArthur JR; Brust A; Bhola RF; Rosengren KJ; Ragnarsson L; Dutertre S; Alewood PF; Christie MJ; Adams DJ; Vetter I; Lewis RJ
Sci Rep; 2018 Sep; 8(1):13397. PubMed ID: 30194442
[TBL] [Abstract][Full Text] [Related]
9. Reversal of Peripheral Neuropathic Pain by the Small-Molecule Natural Product Physalin F via Block of CaV2.3 (R-Type) and CaV2.2 (N-Type) Voltage-Gated Calcium Channels.
Shan Z; Cai S; Yu J; Zhang Z; Vallecillo TGM; Serafini MJ; Thomas AM; Pham NYN; Bellampalli SS; Moutal A; Zhou Y; Xu GB; Xu YM; Luo S; Patek M; Streicher JM; Gunatilaka AAL; Khanna R
ACS Chem Neurosci; 2019 Jun; 10(6):2939-2955. PubMed ID: 30946560
[TBL] [Abstract][Full Text] [Related]
10. Intracerebroventricular administration of N-type calcium channel blocker ziconotide displays anticonvulsant, anxiolytic, and sedative effects in rats: A preclinical and pilot study.
Zamani M; Budde T; Bozorgi H
Epilepsy Behav; 2020 Oct; 111():107251. PubMed ID: 32593873
[TBL] [Abstract][Full Text] [Related]
11. Ziconotide, a new N-type calcium channel blocker, administered intrathecally for acute postoperative pain.
Atanassoff PG; Hartmannsgruber MW; Thrasher J; Wermeling D; Longton W; Gaeta R; Singh T; Mayo M; McGuire D; Luther RR
Reg Anesth Pain Med; 2000; 25(3):274-8. PubMed ID: 10834782
[TBL] [Abstract][Full Text] [Related]
12. Actions of intrathecal omega-conotoxins CVID, GVIA, MVIIA, and morphine in acute and neuropathic pain in the rat.
Scott DA; Wright CE; Angus JA
Eur J Pharmacol; 2002 Sep; 451(3):279-86. PubMed ID: 12242089
[TBL] [Abstract][Full Text] [Related]
13. Ziconotide: can we use it in palliative care?
Prommer EE
Am J Hosp Palliat Care; 2005; 22(5):369-74. PubMed ID: 16225359
[TBL] [Abstract][Full Text] [Related]
14. Ziconotide--a novel neuron-specific calcium channel blocker for the intrathecal treatment of severe chronic pain--a short review.
Klotz U
Int J Clin Pharmacol Ther; 2006 Oct; 44(10):478-83. PubMed ID: 17063978
[TBL] [Abstract][Full Text] [Related]
15. Molecular basis of toxicity of N-type calcium channel inhibitor MVIIA.
Wang F; Yan Z; Liu Z; Wang S; Wu Q; Yu S; Ding J; Dai Q
Neuropharmacology; 2016 Feb; 101():137-45. PubMed ID: 26344359
[TBL] [Abstract][Full Text] [Related]
16. Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke.
Yamamoto T; Takahara A
Curr Top Med Chem; 2009; 9(4):377-95. PubMed ID: 19442208
[TBL] [Abstract][Full Text] [Related]
17. An integrated multiassay approach to the discovery of small-molecule N-type voltage-gated calcium channel antagonists.
Finley MF; Lubin ML; Neeper MP; Beck E; Liu Y; Flores CM; Qin N
Assay Drug Dev Technol; 2010 Dec; 8(6):685-94. PubMed ID: 21050074
[TBL] [Abstract][Full Text] [Related]
18. Spinal antinociception of synthetic omega-conotoxin SO-3, a selective N-type neuronal voltage-sensitive calcium channel blocker, and its effects on morphine analgesia in chemical stimulus tests in rodent.
Yan LD; Liu YL; Zhang L; Dong HJ; Zhou PL; Su RB; Gong ZH; Huang PT
Eur J Pharmacol; 2010 Jun; 636(1-3):73-81. PubMed ID: 20361956
[TBL] [Abstract][Full Text] [Related]
19. Targeting chronic and neuropathic pain: the N-type calcium channel comes of age.
Snutch TP
NeuroRx; 2005 Oct; 2(4):662-70. PubMed ID: 16489373
[TBL] [Abstract][Full Text] [Related]
20. Design, Synthesis and Biological Evaluation of Two Opioid Agonist and Cav 2.2 Blocker Multitarget Ligands.
Mollica A; Costante R; Novellino E; Stefanucci A; Pieretti S; Zador F; Samavati R; Borsodi A; Benyhe S; Vetter I; Lewis RJ
Chem Biol Drug Des; 2015 Aug; 86(2):156-62. PubMed ID: 25393330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
